RxDoctor Payments Data

Omesh Gupta, MD

Ophthalmology · Plymouth Meeting, PANPI 1326268475

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $78,695 of the $84,527 with a category attached, or 93.1%. Alcon accounts for 99.6% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $28,894, 2.0 times the $14,401 reported in 2019. Among ophthalmology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$84,527in general payments, 2019–2025

Across 40 payments — averaging $2113.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$84K
  • Genentech USA, Inc.$282
  • Alimera Sciences, Inc.$18
$20,375in research payments, 2019–2025

Across 3 payments — averaging $6791.67 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Alcon Research LLC$20K

What the payments were for

  • Consulting fees$78,69593%
  • Travel & lodging$4,2505%
  • Food & beverage$1,5822%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Alcon36$84,226
Genentech USA, Inc.3$282
Alimera Sciences, Inc.1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$84,527 in reported general payments places this provider in the 95th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,613,506
Medicare patients
1,884
Services billed
43,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ProlensaBromfenac Sodium111$46,190
Prednisolone Acetate387$18,401
Bromfenac Sodium91$16,262
IlevroNepafenac28$11,140
Brimonidine Tartrate87$3,338
Difluprednate37$2,899
Ketorolac Tromethamine101$2,637
Loteprednol Etabonate13$2,506
Diclofenac Sodium181$1,641
ErythromycinErythromycin Base132$1,461
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat126$1,306
Atropine Sulfate17$738
Latanoprost66$671
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim94$651
Ofloxacin27$550

Paid to pharmacies, not to this prescriber.

Other ophthalmology in Plymouth Meeting

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →